在前性痴呆症中,绘制大脑缩,调解对奖励的不耐烦增加
Valérie Godefroy1,2, Anaïs Durand3, Richard Levy3
1CRNL U1028 UMR5292, Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon, Bron, France. vlrgodefroy@gmail.com.
Communications biology
|January 9, 2026
概括
行为变异前性痴呆症 (bvFTD) 患者对奖励表现出更大的不耐烦,显示出更高的折扣率和对更大的后期奖励的敏感性较低. 特定的大脑区域,包括中间脉动和副海马皮层,调解这些改变的时间间偏好.
科学领域:
- 神经科学是一个神经科学.
- 心理学 心理学 心理学
- 神经学 神经学
背景情况:
- 在精神病和神经退行性疾病中,时间间偏好,或者在较大的后期 (LL) 和较小的早期 (SS) 奖励之间做出选择,经常会发生变化.
- 行为变异前性痴呆症 (bvFTD) 的特点是冲动性和决策网络缩,使其成为研究奖励不耐烦的相关模型.
研究的目的:
- 为了研究bvFTD患者的时间间选择 (ITC) 行为.
- 确定bvFTD中改变奖励偏好的神经相关物和媒介.
- 检查ITC结果与bvFTD症状之间的关系.
主要方法:
- 22名bvFTD患者和17名对照人完成了ITC任务,并获得了金钱和食物奖励.
- 时间间选择结果 (折扣率,LL奖励灵敏度) 在各组之间进行了比较.
- 结构性MRI数据的全脑调解分析被用来识别神经介质.
主要成果:
- bvFTD患者在货币和食物选择方面表现出明显更高的折扣率和对LL奖励的敏感性较低.
- 在bvFTD中货币ITC结果与抑制赤字和执行职能减少相关.
- 中间脉和副海马皮层灰质密度降低调解了bvFTD中观察到的ITC变化.
结论:
- bvFTD与时间间偏好发生显著变化有关,反映出对奖励的不耐烦增加.
- 在bvFTD中改变奖励估值的神经介质包括中枢脉和副海马皮质,这些区域参与了情绪突出.
- 这些结构变化可能作为bvFTD中奖励不耐烦的神经标记.
相关概念视频
01:30Attention-Deficit/Hyperactivity Disorder
736
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
736
01:14Role of Cerebellum and Prefrontal Cortex in Memory
1.0K
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
1.0K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806